GenSight Biologics Raises EUR32m in a Series A Financing for Ophthalmic Gene Therapy
GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a EUR32 million Series A financing.
The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP). The lead product is expected to enter the clinic in 2013 in LHON patients.
“We are delighted to be working with GenSight and the other investors to assist the company in progressing its highly innovative technology and gene-based therapeutics towards the clinic. Gene therapy represents a new frontier in targeting ophthalmic diseases, and GenSight’s expertise and capabilities are outstanding,” said
GenSight is based in
Notes for Editors
About Novartis Venture Fund
The Novartis Venture Funds manages over
Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sector. The company invests at all stages of development and has funds under management of over
Versant Ventures is a leading venture capital firm that specializes in investment in innovative, groundbreaking bio-pharmaceuticals, medical devices, and other life science opportunities. Founded in 1999, the firm consists of an experienced team committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. In addition to an industry-leading biotech-focused team in
Index Ventures is a leading global venture capital firm active in technology and biotechnology investing since 1996. From our offices in
SOURCE GenSight Biologics